CSI Market
Sign In | Register

Novelion Therapeutics Inc (NVLN) Annual Cash Flow Statement

Annual · GAAP · USD millions
Access NVLN quarterly Cash Flow →
Tracking cash flow results across Novelion Therapeutics Inc to helps illustrate how Dec 31 2018's cash generation has responded to changing business conditions.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Annual Report, GAAP in USD millions
ITEM 		(Dec 31 2018)
12 Months 		(Dec 31 2017) (Dec 31 2016)
Operating Activities
Income-108.33
Depreciation & amortization1.73
Amortization of Other Assets28.22
Extraordinary Item, Gain (Loss), Insurance Assets, Accretion Expense0.00
Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Asset0.00
Provision For Loan Losses Expensed0.00
Increase (Decrease) in Inventories0.36
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Property Plant Equipment0.00
Share-based Compensation3.06
Income (Loss) from Equity Method Investments0.00
Financial Instruments and Foreign Currency Transaction46.93
Depreciation Continued And Discontinued Operations-
Recovery On Assets Held For Sale-
Operating Lease Noncash Lease Expense-
Provision for Recovery of Inventory Excess and Obsolescence-
Increase Decrease In Contract With Customer Liability-
Income taxes0.86
Gain (Loss) on Investments0.00
Increase (Decrease) in Accounts Receivable-6.75
Increase (Decrease) in Accounts Payable-10.72
Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities-6.45
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense and Other Assets-4.38
Other Working Capital0.00
Other Noncash Income (Expense)0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities0.00
Discontinued operations0.00
Net Cash flow from Operating Activities-55.47
Investing Activities
Capital Expenditures-0.44
Sale of Capital Items0.00
Short-term Investments Proceeds0.00
Short-term Investments Acq.0.00
Real Estate Investments0.00
Investing Activity Proceeds From Contingent Consideration-
Proceeds From Sale Of Long Lived Assets-
Advances Under Receivables Agreement-
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments to Acquire Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Acquisition Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities-0.44
Financing Activities
Short-term debt Net70.00
Other borrowing transactions-25.47
Long-term debt - borrowings2.50
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock0.35
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net0.00
Payment For Investment-
Proceeds From Sale Of Investment-
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities47.39
Effect of exchange rate on cash flow-1.76
Discontinued operations0.00
Free Cash Flow-55.91
Total Cash Flow-10.28
4 historic quarters locked

Sign in to unlock the full Novelion Therapeutics Inc cash flow history.

Sign In Create Free Account

About NVLN Annual Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-K filings and normalized by CSIMarket.

Source & verification

  • Form: 10-K
  • Filed with the SEC: n/a

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.

Figures are derived from filed reports and may be restated. Historical data is subject to revision.

Untitled Document 





                    


    



  Get the full CSIMarket dataset:
  Subscribe
  API
  License